Table of Contents

Prev Issue
For all checked items
For all checked items

Focus

For all checked items
  • Cancer

    Improving Immunotherapy: Revisiting the Immunologist’s Little Secret

    • Jay A. Berzofsky
    8 February 2012: 120fs4

    Synergy between intracellular and extracellular sensing mechanisms of the innate immune system improves adaptive immune responses to cancer vaccines and clearance of tumors.

Perspective

For all checked items
  • Cancer

    Escaping ALK Inhibition: Mechanisms of and Strategies to Overcome Resistance

    • Christine M. Lovly and
    • William Pao
    8 February 2012: 120ps2

    Two recent studies offer insights on how cancer cells develop resistance to targeted therapies and possible ways to battle this therapeutic bottleneck.

Research Articles

For all checked items
  • Gene Therapy

    AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness

    • Jean Bennett,
    • Manzar Ashtari,
    • Jennifer Wellman,
    • Kathleen A. Marshall,
    • Laura L. Cyckowski,
    • Daniel C. Chung,
    • Sarah McCague,
    • Eric A. Pierce,
    • Yifeng Chen,
    • Jeannette L. Bennicelli,
    • Xiaosong Zhu,
    • Gui-shuang Ying,
    • Junwei Sun,
    • J. Fraser Wright,
    • Alberto Auricchio,
    • Francesca Simonelli,
    • Kenneth S. Shindler,
    • Federico Mingozzi,
    • Katherine A. High,
    • and Albert M. Maguire
    8 February 2012: 120ra15

    Repeat administration of gene therapy to the contralateral retina of three congenitally blind patients was safe and resulted in improved vision.

  • Cancer Vaccines

    Simultaneous Targeting of Toll- and Nod-Like Receptors Induces Effective Tumor-Specific Immune Responses

    • Johan Garaude,
    • Andrew Kent,
    • Nico van Rooijen,
    • and J. Magarian Blander
    8 February 2012: 120ra16

    A cancer vaccine of irradiated tumor cells expressing flagellin primes effective NLRC4/NAIP5- and TLR5-dependent antitumor immune responses.

  • Cancer

    Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

    • Ryohei Katayama,
    • Alice T. Shaw,
    • Tahsin M. Khan,
    • Mari Mino-Kenudson,
    • Benjamin J. Solomon,
    • Balazs Halmos,
    • Nicholas A. Jessop,
    • John C. Wain,
    • Alan Tien Yeo,
    • Cyril Benes,
    • Lisa Drew,
    • Jamal Carlos Saeh,
    • Katherine Crosby,
    • Lecia V. Sequist,
    • A. John Iafrate,
    • and Jeffrey A. Engelman
    8 February 2012: 120ra17. published ahead of print 25 January 2012,

    Multiple mechanisms of crizotinib resistance were identified in lung cancer patients including new secondary ALK mutations and activation of receptor tyrosine kinases.

Editors' Choice

For all checked items
  • GENOMICS

    Treatments for Atrial Fibrillation Get Personal

    • Samir Damani
    8 February 2012: 120ec19

    A pharmacogenomics study identifies a patient population that responds more favorably to heart rate–control medication.

  • Diabetes

    Mayday, Mayday, Mayday! Answering the Distress Call of the β Cell

    • Carmella Evans-Molina
    8 February 2012: 120ec20

    A noninvasive method to measure β-cell death in humans is based on differential epigenetic marks in the insulin promoter.

  • Multiple Sclerosis

    Antibodies on the Brain

    • Richard J. Lin
    8 February 2012: 120ec21

    The central nervous system produces autoantibodies that may be used as markers for multiple sclerosis.

  • Retinitis Pigmentosa

    Eye-Opening Experience

    • Christopher Skelly
    8 February 2012: 120ec22

    Gene therapy preserves the structure and function of photoreceptors in the eyes of dogs that model a human genetic eye disease that leads to incurable blindness.

  • Therapeutic Ultrasound

    Bubble, Bubble, Tumor in Trouble

    • Srini Tridandapani
    8 February 2012: 120ec23

    Microbubble contrast-enhanced ultrasound can disrupt tumor blood vessels and results in tumor necrosis.

Podcast

For all checked items
  • Cancer

    Science Translational Medicine Podcast: 8 February 2012

    • Jeffrey Engelman and
    • Orla Smith
    8 February 2012: 120pc2

    A conversation with Jeffrey Engelman about teasing apart the different molecular mechanisms that result in drug resistance in lung cancer patients.

For all checked items